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ABSTRACT
Objective. The aim of the present work was to evaluate the effects of Lipofundin 20% on lipid 
peroxidation markers in the liver of New Zealand white rabbits. Materials and methods. The 
animals were treated with an intravenous injection (2 ml/kg) of the lipid emulsion during 8 days 
through the marginal ear vein. At the end of the experiment some lipid peroxidation parameters and 
lipid profile were tested through spectrophotography. Results. Lipofundin was found to induce a 
significant (p<0.05) increase of malondialdehyde, total hydroperoxides, and peroxidation potential. 
Also, high levels of total cholesterol, triglycerides, LDL - cholesterol and HDL-cholesterol were 
observed in treated animals compared with the control group (p<0.05). Conclusions. Data proved 
that Lipofundin induces hepatic lipid peroxidation in rabbits, mainly through a mechanism which 
involves an induction of hyperlipidemia
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RESUMEN
Objetivo. El objetivo del presente trabajo fue evaluar los efectos del lipofundin 20% sobre marcadores 
hepáticos de peroxidación lipídica en conejos blancos Nueva Zelanda. Materiales y métodos. Los 
animales fueron tratados con una inyección intravenosa (2 ml/kg) de la emulsión lipídica durante 8 
días por la vena marginal de la oreja. Al final del experimento algunos marcadores de peroxidación 
lipídica y el perfil lipídico fueron espectrofotométricamente determinados. Resultados. Se observó 
que el lipofundin indujo un incremento significativo (p<0.05) de malonildialdehído, hidroperóxidos 
totales y el potencial de peroxidación. También, altos niveles de colesterol total, triglicéridos, 
colesterol de LDL y colesterol de HDL fueron observados en los animales tratados respecto a los del 
grupo control (p<0.05). Conclusiones. Los resultados demostraron que el Lipofundin 20% induce 
peroxidación lipídica hepática en conejos, principalmente a través de un mecanismo que involucra la 
inducción de hiperlipidemia.
Palabras clave: Conejos, estrés oxidativo, hiperlipidemia, lipofundin, peroxidación lipídica (Fuente: DeCS).
Rev.MVZ Córdoba 17(3):3113-3117, 2012.
ORIGINAL3114 REVISTA MVZ CÓRDOBA  •  Volumen 17(3)  Septiembre - Diciembre  2012
INTRODUCTION 
Lipid  peroxidation  (LPO)  was  first  studied  in 
the 1930’s in relation to food deterioration, but 
since then, there has been increasing evidence 
showing the involvement of free radicals in 
biology, leading to renewed attention on LPO 
with a wider scope in the fields of chemistry, 
biochemistry, nutrition and medicine (1,2), 
amongst others. Further studies revealed that, 
like proteins, carbohydrates, and nucleic acids, 
lipids are targets of reactive oxygen species 
(ROS) and become oxidized to render cytotoxic 
products (3). Several oxidized products 
have been studied and also used as LPO 
biomarkers, such as malondialdehyde (MDA) 
and lipoperoxides (LOOH) (4).
Artificial  fat  emulsions  are  widely  used  in 
parenteral nutrition. The soya oil-based fat 
emulsions represent a major part of energy 
and are also a necessary source of essential 
fatty  acids  in  the  mentioned  therapy  (5,6). 
Lipofundin 10% constitutes a frequently 
indicated fat emulsion as a source of calories 
for patients requiring parenteral nutrition, 
but preclinical investigations demonstrated 
that Lipofundin 20% induces atherosclerotic 
lesion formation in rabbits (7). Our group also 
demonstrated that this fat emulsion induces 
a systemic LPO in rabbits (8), but the effects 
on hepatic LPO have not been assessed. 
Therefore, the purpose of the present work is 
to evaluate the effects of Lipofundin 20% on 
lipid profile and hepatic biomarkers of LPO in 
New Zealand White rabbits (NZB).
MATERIALS AND METHODS
Animals. Standard NZW male rabbits, weighing 
2.0-2.5  kg  and  12  weeks  old,  were  obtained 
from CENPALAB (Mayabeque, Cuba). Rabbits 
were housed under conventional conditions 
exposed to a 12 hr light-dark cycle with free 
access to water and food. Animal studies were 
performed with approval of the Pharmacy and 
Food Sciences College Institutional Animal 
Ethical Committee. All procedures were in 
accordance with the European Union Guidelines 
for animal experimentation.
Lipofundin composition. Lipofundin MCT/
LCT 20% (Braun Melsungen AG, Melsungen, 
Germany) is a lipid emulsion containing soya 
oil 100 g, medium-chain triglycerides 100 g, 
glycerol 25 g, egg lecithin 12 g, α-tocopherol 
170 ± 40 mg, and sodium oleate/water for 
injection in sufficient quantity to 1000 ml. 
Experimental design. Two groups of 10 
rabbits were used in the study. The first group 
received an intravenous injection of phosphate-
buffered saline solution (PBS), pH 7,4 (control 
group), and the second one received a slow 
intravenous injection of 2 ml/kg of Lipofundin 
MCT/LCT 20%, as an infusion during 1-2 min 
(7). This procedure was repeated daily during 
a period of 8 days. On day 9, the animals were 
anesthetized  with  ketamine  hydrochloride  (5 
mg/kg i.m.), and euthanized with an overdose 
of sodium pentobarbital (90 mg/kg, i.v.). 
(Abbott Laboratories, México SA de CV, México). 
Then, the liver was perfused with NaCl 0.9% 
solution at 4ºC.
Liver homogenate preparation. The hepatic 
right lobe of each animal was extracted and 
homogenized in 20mM KCl/histidine buffer, 
pH 7.4, 1:10 w/v using a tissue homogenizer 
(Edmund Bühler LBMA, Germany) at 4ºC and 
centrifuged for 10 min at 12000 g. Supernatants 
were taken for biochemical determination.
Serum sample collection. Blood samples (1 
ml) were obtained on day 0 and 9 (at the end of 
the study), for biochemical analyses. Blood was 
withdrawn from the rabbit’s marginal ear vein. 
These samples were immediately centrifuged 
at 2500 g, at 4ºC for 10 min. The serum was 
collected and aliquots were stored at -80ºC until 
analysis. 
Serum lipid assay. Total cholesterol, 
triglycerides, LDL-cholesterol and HDL-cholesterol 
Serums were determined using commercial 
enzymatic kits (Randox, Crumlin, UK).
Redox biomarkers determination. All 
biochemical parameters were determined 
through spectrophotometric methods using a 
Pharmacia 1000 Spectrophotometer (Pharmacia 
LKB, Uppsala, Sweden). Total protein levels 
were determined using the method described 
by Bradford (9) with bovine albumin serum as 
standard. 
Total hydroperoxides (ROOH) were measured 
through  Bioxytech  H2O2-560  kit  (Oxis 
International Inc., Portland, OR, USA). The 
assay is based on the oxidation of Fe2+ to Fe3+ 
by hydroperoxides under acidic conditions. 
Ferric ions bind with indicator xylenol 
orange (3.3`-bis(N,N-di(carboxymethyl)-
aminomethyl)-o-cresolsulfone-phtalein, sodium 
salt) to form a stable colored compound, which 
can be measured at 560 nm.
MDA Concentration was determined using the 
LPO-586 kit obtained from Calbiochem (La Jolla, 3115
CA, USA). In the evaluation, the production of a 
stable chromophore after 40 min of incubation 
at 45ºC was measured at 586 nm. For control, 
freshly prepared solutions of malondialdehyde 
bis [dimethyl acetal] (Sigma St Louis, MO, USA) 
were employed and evaluated under identical 
conditions (10). 
In order to determine susceptibility to lipid 
peroxidation and total reactive antioxidant 
power (TRAP), the samples were incubated with 
a solution of copper sulphate (final concentration 
2 mM) at 37ºC for 24 h. The peroxidation 
potential (PP) was calculated by subtracting the 
MDA levels before the induction of LPO from the 
one obtained at 24h (11). 
Statistical analysis. Statistical analysis was 
performed using the SPSS program for Windows 
(version  11.5,  SPSS  Inc).  Bartlett’s  Box-test 
was used to test the homogeneity of variance. 
Differences between groups were determined 
by independent student’s t-test (two-tailed). 
Data was expressed as the mean ± standard 
deviation (SD). A P-value <0.05 was considered 
as statistically significant.
RESULTS
Serum total cholesterol, triglycerides, LDL-
cholesterol and HDL-cholesterol levels showed 
a significant increase (p<0.05) in those animals 
who were treated during 8 days with the lipid-
rich emulsion Lipofundin, compared with the 
control (Table 1). These parameters were 
determined on day 0 and statistical differences 
were not shown (data not shown). 
animals compared with controls. Total ROOH 
levels were also significantly higher (p<0.05) 
in the animals that were administered with 
lipofundin than in non-treated specimens. 
Besides, lipofundin treatment also caused 
an increase in PP compared with the control 
group (p<0.05).
DISCUSSION
After lipofundin administration, high levels of 
triglycerides, total cholesterol, LDL-cholesterol 
and HDL-cholesterol serums were observed. 
Indeed, there is a causal relationship between 
elevated plasma lipids and the occurrence of 
LPO (12). 
Lipofundin 20%-induced hyperlipidemia could be 
associated with the high content of triglycerides 
in this emulsion. High levels of exogenous 
triglycerides promote ApoB100 and cholesterol 
synthesis, and eventually the assembly of very 
low-density lipoproteins (VLDL) (13). In fact, 
these results are in accordance with our previous 
report (8), while it is known that lipofundin 
10% caused a 60% increase in total serum 
cholesterol after parenteral administration in a 
human study (5). 
In addition, there is a mutual lipid and 
apolipoprotein exchange between serum 
lipoproteins and infused triglyceride/
phospholipid particles (14). The increase of 
HDL-cholesterol may be determined by a 
physiological response against the elevated 
LDL-cholesterol levels. 
This study demonstrated that lipofundin-
induced hyperlipidemia induces liver oxidative 
stress. Strong evidence of the involvement of 
increased free radical production in the onset 
of hyperlipidemia has been reported previously 
(15). Also, lipofundin was recently demonstrated 
to induce an increase of serum lipids in rabbits 
(7) and in rats (16).
Table 1.  Effects of Lipofundin 20% on serum lipids
Biomarkers Control group Lipofundin group
TC, mmol/L  0.99 ± 0.05 2.89 ± 0.11*
TG, mmol/L  1.21 ± 0.03 2.66 ± 0.09*
HDLc, mmol/L  0.59 ± 0.09 1.18 ± 0.03*
LDLc, mmol/L  0.21 ± 0.03 0.96 ± 0.05*
Legend: The serum lipid levels were similar between groups at the 
beginning of the experiment, also it was observed no differences of 
lipid levels between day 0 and 9 in controls (data not shown). Data 
are the means ± standard deviation. Asterisks represent statistical 
differences  (p<0.05).  The  samples  were  tested  for  triplicate  in  all 
performed assays. TC: total cholesterol, TG: triglycerides, HDLc: 
cholesterol of high-density lipoprotein, LDLc: cholesterol of low-
density lipoprotein.
Table 2.  Effects of Lipofundin 20% on hepatic lipid 
peroxidation biomarkers.
Biomarkers Control group Lipofundin group
MDA (µmol/L/mgPr) 3.89 ± 0.75 7.63 ± 0.31*
TH (μmol/L/mgPr) 35.27 ± 4.22 67.32 ± 5.89*
PP (μmol/L of MDA/mg Pr) 5.06 ± 0.48 9.74 ± 0.42*
Legend: Data are the means ± standard deviation. Asterisks represent 
statistical differences (p<0.05). The concentration of all biomarkers 
is expressed per milligrams of total proteins (Pr). The samples were 
tested for triplicate in all performed assays. MDA: malondialdehyde, 
TH: total hydroperoxides, PP: peroxidation potential.
Table 2 shows the behavior of hepatic biomarkers 
of LPO in both groups. The damages on lipids were 
significantly (p<0.05) modified after 8 days of 
Lipofundin administration compared to the non-
treated group. At the end of the experimental 
period the MDA levels, one of the end-products 
of LPO, were higher in lipofundin treated 
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In vitro LPO mechanisms, dynamics, and 
products have been studied extensively and 
are now fairly well understood and documented 
(17). Lipid hydroperoxides and hydrogen 
peroxide (H2O2) generated by LPO play a central 
role in many diseases such as atherosclerosis, 
mainly during endothelial dysfunction (18). 
Transition metals (iron or copper) may produce 
H2O2 decomposition and cause the generation 
of the highly toxic and reactive hydroxyl radical 
(•OH),  which  reacts  with  cellular  components 
(19). High ROOH concentration detected in 
rabbits treated with lipofundin 20% may be a 
blank for free transition metals attack. ROOH 
decomposition affects the delicate balance 
between antioxidants and pro-oxidant factors, 
which can leads to oxidative stress states.  
An increasing MDA level in those animals 
treated with lipofundin 20% was also detected 
in this study. Our data is in accordance with 
the criteria that this end-product of LPO and 
is strongly associated with the development of 
hyperlipidemia (20). 
Lipofundin-induced high serum lipid levels, 
especially atherogenic ones such as cholesterol 
and LDL allow to explain, in part, the fact that 
these were higher in animals administered 
with LPO products than in controls.  MDA is 
considered as a major epitope of oxidized LDL 
(21), suggesting that lipofundin 20% induces 
an increase in LPO closely associated with an 
elevation of LDL particles and related ApoB100-
containing lipoproteins. Also, PP increase in 
livers from treated rabbits reinforces the criteria 
that LPO is determinant in the loss of redox 
hepatic status in former animals which were 
under Lipofundin 20% treatment. 
In conclusion, the present study demonstrated 
that lipofundin 20% induces hyperlipidemia, 
thereby promoting hepatic LPO. Our data 
shows novel evidences of lipofundin-induced 
oxidative damages on hepatic lipids. These 
results reinforce the attractive characteristics 
of lipofundin to be used as an experimental 
inductor of LPO in rabbits.
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